References
- Burden-Teh E, Thomas KS, Ratib S, et al. The epidemiology of childhood psoriasis: a scoping review. Br J Dermatol. 2016;174(6):1242–1257.
- Navarini AA, Burden AD, Capon F, et al. European consensus statement on phenotypes of pustular psoriasis. J Eur Acad Dermatol Venereol. 2017;31(11):1792–1799.
- Rios C, Pope E, Lara‐Corrales I. A systematic review of systemic medications for pustular psoriasis in pediatrics. Pediatr Dermatol. 2014;31(4):430–439.
- Huang YW, Tsai TF. Pharmacological management of pediatric pustular psoriasis. Paediatr Drugs. 2020;22(3):265–277.
- Imafuku S, Honma M, Okubo Y, et al. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: a 52-week analysis from phase III open-label multicenter Japanese study. J Dermatol. 2016;43(9):1011–1017.
- Ho PH, Tsai TF. Successful treatment of refractory juvenile generalized pustular psoriasis with secukinumab monotherapy: a case report and review of published work. J Dermatol. 2018;45(11):1353–1356.
- Köstner K, Prelog M, Almanzar G, et al. Successful use of secukinumab in a 4-year-old patient with deficiency of interleukin-36 antagonist. Rheumatology (Oxford). 2018;57(5):936–938.